Glucose tetrasaccharide (Glc4) is used as a reference in analysis of urinary glucose tetrasacchaide, a biomarker for Pompe disease and other glycogen storage diseases.
Verpackung
Bottomless glass bottle. Contents are inside inserted fused cone.
Sonstige Hinweise
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Journal of immunological methods, 68(1-2), 217-226 (1984-03-30)
Monoclonal antibodies were produced in BALB/cJ mice against a urinary glucose-containing tetrasaccharide (Glc)4 coupled to keyhole limpet hemocyanin (KLH). The immune response was studied using 7 different strains of mice and 11 different immunization protocols. From 6 fusions using the
Molecular genetics and metabolism, 85(4), 247-254 (2005-05-12)
A tetraglucose oligomer, Glcalpha1-6Glcalpha1-4Glcalpha1-4Glc, designated Glc4, has been shown to be a putative biomarker for the diagnosis of Pompe disease. The purpose of this study was to assess whether Glc4 could be used to monitor the therapeutic response to recombinant
Journal of the neurological sciences, 244(1-2), 59-68 (2006-02-17)
There is an unmet need to develop specific biomarkers for multiple sclerosis (MS) to aid in the diagnosis, improve the management of patients and the monitoring of the effectiveness of treatment. We have screened serum from patients with relapsing-remitting MS
In the present work we have explored conditions for using a pulsed amperometric detector for on-line analysis of oligosaccharides eluted from a high-performance liquid affinity chromatography column. A monoclonal antibody that specifically binds a glucose-containing oligosaccharide is coupled to a
Genetics in medicine : official journal of the American College of Medical Genetics, 11(7), 536-541 (2009-06-13)
To investigate the correlation of the urinary glucose tetrasaccharide, Glcalpha1-6Glcalpha1-4Glcalpha1-4Glc, (Glc4) with skeletal muscle glycogen content and the long-term clinical response to enzyme replacement therapy with recombinant human acid alpha glucosidase in infantile Pompe disease. Eighteen patients, < or =6
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
